About US
Contact us
-
Merck agrees to acquire UK's IOmet PharmaMerck has entered into an agreement to acquire IOmet Pharma, a UK-based small-molecule drug developer focused on cancer immunotherapy and cancer metabolism, for an undisclosed price. Following comple2016/1/18
-
Sanofi and Warp Drive to develop new oncology therapies and antibioticsFrench pharmaceutical firm Sanofi has entered into a new collaboration with Warp Drive Bio, a US-based biotechnology firm using the molecules and mechanisms of nature to discover and develop transform2016/1/18
-
Boehringer and Arena to develop new drugs for psychiatric diseasesGerman pharmaceutical firm Boehringer Ingelheim has signed an exclusive agreement with US-based Arena Pharmaceuticals, to conduct joint research to discover new drug candidates for psychiatric disease2016/1/15
-
Sanofi and Warp Drive to develop new oncology therapies and antibioticsFrench pharmaceutical firm Sanofi has entered into a new collaboration with Warp Drive Bio, a US-based biotechnology firm using the molecules and mechanisms of nature to discover and develop transform2016/1/15
-
GSK chief Witty opens up to spinoff talk, with consumer health an obvious choiceGlaxoSmithKline ($GSK) CEOAndrew Wittymay be coming around on a breakup. At theJ.P. Morgan Healthcare Conference, Witty said he's open to the idea and pegged his consumer health joint venture with Nov2016/1/14
-
New Bayer site to make traditional Chinese and Western consumer health medsBayersnapped up China's Dihon in 2014 with the idea of combining Dihon's traditional Chinese medicines with Bayer's Western OTC products in a major consumer health play in the country. Now it has a la2016/1/14
-
Time for J&J to pay up in $124M Risperdal case as SCOTUS deflects final appealJohnson & Johnson ($JNJ) fell short Monday in its final effort to escape a Risperdal marketing penalty in South Carolina. TheU.S. Supreme Courtdeclined to take up J&J's last appeal in the case2016/1/13
-
Want the skinny from the J.P. Morgan Healthcare Conference? We've got you coveredSAN FRANCISCO--Sometimes, it can tough to be filter out what a company means from the little it says at theJ.P. Morgan Healthcare Conference. So please, allow us to do the summarizing--and check back2016/1/13
-
Pharma scandals spawn investor lawsuits at KaloBios, SequoiaAngry investors ofKaloBiosand Sequoia Fund are taking their pharma grievances to the courts. Shareholders at KaloBios--formerly led by pharma bad boyMartin Shkreli--are suing to get back the $5.4 mill2016/1/12
-
What public outcry? New year brings dozens of double-digit drug price hikesAll eyes may be on rising drug costs, but that doesn't mean pharma companies are backing away from price hikes. In recent days, analysts have spotlighted hundreds of increases, more than 100 of them a2016/1/12